A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Confession: the initial experience of catharsis the patient experiences as a result of sharing secrets and private experiences. Elucidation: similar to Freud's interpretation, the examination of symptoms and transference phenomena, and the location of areas of failed development. Education: the insights of stages (1) and (2) start to be seen in the patient's life, and there is an improved ability to adapt to society's demands Transformation: Individuation commences and 'selfhood' begins, which also involves a confrontation with the shadow, anima/animus, and other archetypal components. Unlike traditional Freudian analysis, which requires an analyst to see their patient five times a week, Jung saw his patients twice a week, and then reduced this to one, also taking breaks every ten or so weeks. He saw what the patient did in their time outside of the sessions as equally, if not more, important than their time in the sessions. He also saw a reliance on the therapist as something that would thwart the patient's progress, so this method prevented this. The breaks also help the analyst to keep vitality in their life and their therapy practice, not being reduced by the work (or 'burnt out' as we now call it). Jung saw it as an imperative for trainees of psychotherapy to have their own analysis, and after qualifying continue to undertake self-analysis.
=== Hungarian === Megszentségteleníthetetlenségeskedéseitekért, with 44 letters, is the longest word in the Hungarian language, and approximately means "for your [plural] continued behaviour as if you could not be desecrated". It is already morphed, since Hungarian is an agglutinative language. For instance összetöredezettségmentesíthetetlenségeskedéseitekért, with 52 letters shares most of the postfixes of the original word, but changed the base word to tör (break in english). The Hungarian language has many causes for writing words together, but there are a few rules for avoiding undisciplined length, resulting in unreadability. Words with less than six syllables can be written in one. Agglutinated words have to be separated by one dash, if they are more than six syllables altogether. If there are more than two words that are already written with a dash and more are needed, a new dash must be used to add it (like C-vitamin-adagolás, meaning "Vitamin C rationing"). In cases where two long words would be written, it may be advised that they be used separately (possible: békeszerződéstervezet-kidolgozás meaning "peace agreement plan–elaboration", but advised rather a békeszerződés tervezetének kidolgozása meaning "the elaboration of the plan of the peace agreement").
Metal-binding proteins are proteins or protein domains that chelate a metal ion. They are a subgroup of metalloproteins. Binding of metal ions via chelation is usually achieved via histidines or cysteines. In some cases this is a necessary part of their folding and maintenance of a tertiary structure. Alternatively, a metal-binding protein may maintain its structure without the metal (apo form) and bind it as a ligand (e.g. as part of metal homeostasis). In other cases a coordinated metal cofactor is used in the active site of an enzyme to assist catalysis.
Further studies demonstrate that supportive settings significantly reduce the likelihood of adverse reactions, including panic, paranoia, or psychological distress. Positive therapeutic outcomes are strongly correlated with the participant's trust in the environment and the facilitators.
Sources: en.wikipedia.org
Materials in certain cosmetics such as sun cream, moisturizer, and deodorant may have potential benefits from the use of nanochemistry. Manufacturers are working to increase the effectiveness of various cosmetics by facilitating oil nanoemulsion. These particles have extended the boundaries in managing wrinkling, dehydrated, and inelastic skin associated with aging. In sunscreen, titanium dioxide and zinc oxide nanoparticles prove to be effective UV filters but can also penetrate through skin. These chemicals protect the skin against harmful UV light by absorbing or reflecting the light and prevent the skin from retaining full damage by photoexcitation of electrons in the nanoparticle.
==== Males ==== CPA has been found to be effective in the treatment of acne in males, with marked improvement in symptoms observed at dosages of 25, 50, and 100 mg/day in different studies. It can also halt further progression of scalp hair loss in men. Increased head hair and decreased body hair has been observed with CPA in men with scalp hair loss. However, its side effects in men, such as demasculinization, gynecomastia, sexual dysfunction, bone density loss, and reversible infertility, make the use of CPA in males impractical in most cases. In addition, lower dosages of CPA, such as 25 mg/day, have been found to be better-tolerated in men. But such doses also show lower effectiveness in the treatment of acne in men.
== Adverse effects == The most common adverse reactions (≥30% occurrence, leading to a 5% treatment discontinuation rate) observed with sirolimus in clinical studies of organ rejection prophylaxis in individuals with kidney transplants include: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, pain, constipation, hypertriglyceridemia, hypertension, increased creatinine, fever, urinary tract infection, anemia, arthralgia, and thrombocytopenia. The most common adverse reactions (≥20% occurrence, leading to an 11% treatment discontinuation rate) observed with sirolimus in clinical studies for the treatment of lymphangioleiomyomatosis are: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, chest pain, stomatitis, nasopharyngitis, acne, upper respiratory tract infection, dizziness, and myalgia. The following adverse effects occurred in 3–20% of individuals taking sirolimus for organ rejection prophylaxis following a kidney transplant:
Sources: en.wikipedia.org
=== Tom Wolsey === Tom Wolsey (Harry Hadden-Paton) is the newly-appointed CEO of Pierpoint, brought on to help steer the firm through its debt crisis. Tom assembles an emergency committee of senior executives to help salvage Pierpoint when its stock plummets the day of its 150th anniversary. After several failed attempts to find a buyer for the firm, Eric finally brokers a sale with Al-Mi'raj, a firm representing the Egyptian sovereign wealth fund. Tom is fired as CEO because the Egyptian government would not approve of his homosexuality.
As suggested by the name, the biomass of the mycosymbiont is mostly exterior to the plant root. The fungal structure is composed primarily of three parts: 1) the intraradical hyphae making up the Hartig net; 2) the mantle that forms a sheath surrounding the root tip; and 3) the extraradical hyphae and related structures that spread throughout the soil.
== Awards == 1977, Young Investigator award, National Institutes of Health (NIH) 1979, Research Career Development Award, NIH 1983, Recognition Award for Young Scholars, American Association of University Women 1987, John J. Abel Award in Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET) Limbird was the second woman to receive this award, the first being Eva King Killam in 1954. 1989, MERIT Award, NIH 1994, Distinguished Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD, now Brain & Behavior Research Foundation). 1998, Distinguished Alumni Award, College of Wooster 2004, Goodman and Gilman Award in Drug Receptor Pharmacology, ASPET 2013, Julius Axelrod Award, ASPET.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.